No Data
No Data
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
Rani Therapeutics Hldgs Analyst Ratings
Rani Therapeutics Advances in Biotherapeutics Market
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)
Maxim Group Remains a Buy on Rani Therapeutics Holdings (RANI)
Rani Therapeutics' Weight-Loss Drugs Can Serve Specific Needs -- Market Talk
No Data
No Data